About avadel pharmaceuticals - AVDL
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
AVDL At a Glance
Avadel Pharmaceuticals Plc
10 Earlsfort Terrace
Dublin, Dublin 02
| Phone | 353-1-901-5201 | Revenue | 27.96M | |
| Industry | Pharmaceuticals: Major | Net Income | -160,276,000.00 | |
| Sector | Health Technology | Employees | 154 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
AVDL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 40.484 |
| Price to Book Ratio | 15.301 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.807 |
| Enterprise Value to Sales | 37.992 |
| Total Debt to Enterprise Value | 0.033 |
AVDL Efficiency
| Revenue/Employee | 181,577.922 |
| Income Per Employee | -1,040,753.247 |
| Receivables Turnover | 2.083 |
| Total Asset Turnover | 0.12 |
AVDL Liquidity
| Current Ratio | 3.641 |
| Quick Ratio | 3.36 |
| Cash Ratio | 2.852 |
AVDL Profitability
| Gross Margin | 90.659 |
| Operating Margin | -492.969 |
| Pretax Margin | -574.963 |
| Net Margin | -573.172 |
| Return on Assets | -68.899 |
| Return on Equity | -481.353 |
| Return on Total Capital | -130.176 |
| Return on Invested Capital | -165.713 |
AVDL Capital Structure
| Total Debt to Total Equity | 40.329 |
| Total Debt to Total Capital | 28.739 |
| Total Debt to Total Assets | 13.551 |
| Long-Term Debt to Equity | 39.287 |
| Long-Term Debt to Total Capital | 27.98 |